Emerging studies suggest Retatru tide , a dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , appears to offer a significant advancement for obesity management . Early patient trials have demonstrated substantial losses in body fat , potentially surpassing existing obesity therapies . Nevertheless , additional ass